$XBIT
XBiotech Inc

2019 Q3 Form 10-Q Financial Statement

#000117184319007437 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.580M $1.180M $1.670M
YoY Change 33.9% -28.92% -27.07%
% of Gross Profit
Research & Development $4.533M $3.940M $3.949M
YoY Change 15.05% -20.08% -46.63%
% of Gross Profit
Depreciation & Amortization $600.0K $620.0K $610.0K
YoY Change -3.23% 106.67% 110.34%
% of Gross Profit
Operating Expenses $6.111M $5.115M $5.621M
YoY Change 19.47% -22.42% -41.98%
Operating Profit -$6.111M -$5.115M -$5.621M
YoY Change 19.47% -22.42% -41.98%
Interest Expense -$40.00K $60.00K -$290.0K
YoY Change -166.67% -84.62% -151.79%
% of Operating Profit
Other Income/Expense, Net -$39.00K $64.00K -$286.0K
YoY Change -160.94% -83.51% -151.53%
Pretax Income -$6.150M -$5.050M -$5.910M
YoY Change 21.78% -18.68% -35.27%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.150M -$5.051M -$5.907M
YoY Change 21.76% -18.6% -35.32%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.15 -$141.0K -$165.0K
COMMON SHARES
Basic Shares Outstanding 41.01M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.30M $20.80M $24.80M
YoY Change 93.75% -46.67% -45.97%
Cash & Equivalents $40.34M $20.85M $24.85M
Short-Term Investments
Other Short-Term Assets $600.0K $500.0K $900.0K
YoY Change 20.0% -61.54% -35.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.91M $21.31M $25.77M
YoY Change 92.02% -47.12% -45.53%
LONG-TERM ASSETS
Property, Plant & Equipment $25.73M $27.94M $28.52M
YoY Change -7.9% -8.04% -6.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $25.73M $27.94M $28.52M
YoY Change -7.9% -8.04% -6.6%
TOTAL ASSETS
Total Short-Term Assets $40.91M $21.31M $25.77M
Total Long-Term Assets $25.73M $27.94M $28.52M
Total Assets $66.64M $49.24M $54.29M
YoY Change 35.33% -30.32% -30.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.061M $878.0K $1.455M
YoY Change 20.84% -60.54% -57.02%
Accrued Expenses $960.0K $1.422M $1.301M
YoY Change -32.49% 11.35% 1.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.021M $2.300M $2.756M
YoY Change -12.13% -34.32% -40.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.021M $2.300M $2.756M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.021M $2.307M $2.768M
YoY Change -12.4% -34.5% -40.92%
SHAREHOLDERS EQUITY
Retained Earnings -$255.6M -$231.6M -$226.5M
YoY Change 10.35% 10.64% 11.54%
Common Stock $320.1M $278.9M $278.4M
YoY Change 14.79% 0.65% 0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.62M $46.94M $51.52M
YoY Change
Total Liabilities & Shareholders Equity $66.64M $49.24M $54.29M
YoY Change 35.33% -30.32% -30.26%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$6.150M -$5.051M -$5.907M
YoY Change 21.76% -18.6% -35.32%
Depreciation, Depletion And Amortization $600.0K $620.0K $610.0K
YoY Change -3.23% 106.67% 110.34%
Cash From Operating Activities -$4.980M -$3.990M -$3.900M
YoY Change 24.81% -38.24% -53.96%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$30.00K -$50.00K
YoY Change 433.33% -88.46% -82.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$160.0K -$30.00K -$50.00K
YoY Change 433.33% -88.46% -82.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 280.0K 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.980M -3.990M -3.900M
Cash From Investing Activities -160.0K -30.00K -50.00K
Cash From Financing Activities 280.0K 0.000 0.000
Net Change In Cash -4.860M -4.020M -3.950M
YoY Change 20.9% -39.73% -51.77%
FREE CASH FLOW
Cash From Operating Activities -$4.980M -$3.990M -$3.900M
Capital Expenditures -$160.0K -$30.00K -$50.00K
Free Cash Flow -$4.820M -$3.960M -$3.850M
YoY Change 21.72% -36.13% -52.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31768000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20849000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24515000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10919000
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1653000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
960000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1291000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
58000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-255000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
797000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
438000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1853000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1186000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
797000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
439000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1853000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1186000
CY2019Q3 us-gaap Assets
Assets
66643000
CY2018Q4 us-gaap Assets
Assets
44345000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
40911000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17016000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40338000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15823000
CY2019Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41066467
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35899772
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
320130000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
279353000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5876000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5023000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17553000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14612000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div>
CY2019Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3000
us-gaap Depreciation
Depreciation
1795000
us-gaap Depreciation
Depreciation
1816000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
313000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
415000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-289000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-36000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-333000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-411000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1578000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1175000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4169000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4004000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
5115000
us-gaap Operating Expenses
OperatingExpenses
17922000
us-gaap Operating Expenses
OperatingExpenses
14886000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6111000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5115000
us-gaap Investment Income Net
InvestmentIncomeNet
379000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-592000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-853000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-331000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
360000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-11000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-620000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1108000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
250000
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
100000
us-gaap Investment Income Net
InvestmentIncomeNet
270000
CY2019Q3 us-gaap Liabilities
Liabilities
2021000
CY2018Q4 us-gaap Liabilities
Liabilities
2947000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66643000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44345000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2021000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2944000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38924000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-198000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14524000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11421000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6150000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5051000
us-gaap Net Income Loss
NetIncomeLoss
-17866000
us-gaap Net Income Loss
NetIncomeLoss
-15027000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
64000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
56000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-141000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6111000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17922000
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-14886000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
274000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
28000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
313000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
415000
CY2019Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2018Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
10000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114000
CY2019Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2018Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
573000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1193000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1135000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
201000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
401000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
939000
CY2018Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25732000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27329000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4533000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3940000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13753000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10882000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-255566000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237700000
us-gaap Share Based Compensation
ShareBasedCompensation
1853000
us-gaap Share Based Compensation
ShareBasedCompensation
1186000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
225959
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
832500
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.66
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
51522000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
46937000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
41398000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
60162000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.45
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5535439
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5813770
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
161000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
255000
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
63000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
328210
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
288000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
37487000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
69413000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
64622000
CY2018Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
200000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div></div></div>
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41019230
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35819772
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38190584
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35795881
xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
1135000
xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
201000
xbit Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
37487000
xbit Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
302000
xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
xbit Stock Issued During Period Value Collection Of Stock Subscription
StockIssuedDuringPeriodValueCollectionOfStockSubscription
302000

Files In Submission

Name View Source Status
0001171843-19-007437-index-headers.html Edgar Link pending
0001171843-19-007437-index.html Edgar Link pending
0001171843-19-007437.txt Edgar Link pending
0001171843-19-007437-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_111219p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20190930.xml Edgar Link completed
xbit-20190930.xsd Edgar Link pending
xbit-20190930_cal.xml Edgar Link unprocessable
xbit-20190930_def.xml Edgar Link unprocessable
xbit-20190930_lab.xml Edgar Link unprocessable
xbit-20190930_pre.xml Edgar Link unprocessable